

SCALING UP SYNERGIES BETWEEN THE GLOBAL FUND AND INNOVATORS TO BREAK DOWN BARRIERS TO HEALTH INNOVATION FOR THE MOST VULNERABLE

A preprogramme event ahead of the
6th Global Fund Replenishment Conference
Lyon - France | Oct. 8th, 2019



DNDi
Design for Neglected Diseases initiative

FIND
Increase diagnosis, restore

INTERNATIONAL PARTNERSHIP FOR MICROBICIDES

IVCC

MMV
Medicines for Malaria Venture

PATH
100000000

TB Alliance

Images: 1/ Toby Hadden - 2/ Anna Wang - 3/ Pearl Gan - 4/ Sergei Supinsky/AFP/Getty Images

SPEAKER PROFILES

Opening Session - Welcome: *Stéphanie Seydoux, French Ambassador for Global Health*



Stéphanie Seydoux was appointed French Ambassador for Global Health in May 2018. She previously served as the head of the Women's Rights and Gender Equality Division and assistant to the Director General of Women's Affairs and Social Cohesion from 2014 to 2017. Since November 2017, she was in charge of a support mission to the government for the revision of the bioethics law.

After starting her career at the Ministry of Foreign Affairs, Stéphanie Seydoux joined the General Inspectorate of Social Affairs (IGAS) in 2004. From 2007 to 2010, she was responsible for the promotion of equality in the High Authority for the Fight against Discrimination and for Equality (HALDE). From 2010 to 2013, she joined the Ministry of Foreign Affairs as first advisor and assistant to the head of post at the French Embassy in Kenya.

Stéphanie SEYDOUX holds a master's degree in literature from the University of Oxford, and is a graduate of the Paris Institute of Political Studies (Sciences Po) as well as a former student of the National School of Administration (ENA) - promotion "Léopold Sédar Senghor"

Opening remarks

Michèle Boccoz, Director-General Envoy for Multilateral Affairs, WHO



Michèle Boccoz has been appointed Director-General's Envoy for Multilateral Affairs. An experienced diplomat from France, her involvement in health diplomacy dates back to her term of office in Geneva, during which she participated in Dr Gro Harlem Brundtland's transition into the WHO Director-General role. She has also served as the French Government's Ambassador for the fight against HIV/AIDS and communicable diseases since 2016. She was equally instrumental in supporting the International Health Regulations and emergency preparedness and response efforts. Furthermore, during the French presidency of the European Union, she coordinated the European Union's positions for the negotiations on the Framework Convention on Tobacco Control. Furthermore, from 2001 to 2007, she was the Executive Director for International Affairs at the Institute Pasteur.

Prior to her current appointment, she worked in various capacities including First Secretary to the Permanent Representation of France to the Organization for Security and Co-operation in Europe, First Secretary to the Permanent Mission of France to the United Nations Office in Geneva, Deputy Chief of Staff to the Minister of Foreign Affairs and Ambassador to Belgium and, later, Croatia.

Ms Boccoz was trained in diplomacy and is an alumna of France's Ecole Normale Supérieure and École Nationale d'Administration (National School of Public Administration).

SCALING UP SYNERGIES BETWEEN THE GLOBAL FUND AND INNOVATORS TO BREAK DOWN BARRIERS TO HEALTH INNOVATION FOR THE MOST VULNERABLE

A preprogramme event ahead of the
6th Global Fund Replenishment Conference
Lyon – France | Oct. 8th, 2019



DNDi
Design for Neglected Diseases initiative

FIND
Increase diagnosis, reduce deaths

INTERNATIONAL PARTNERSHIP FOR MICROBICIDES

IVCC
International Vaccine Centre

MMV
Medicines for Malaria Venture

PATH
Program on Appropriate Technology

TB Alliance

Images: 1/ Toby Hadden - 2/ Anna Wang - 3/ Pearl Gan - 4/ Sergei Supinsky/AFP/Getty Images

Catherina Boehme, *CEO FIND*



Catharina Boehme has been CEO of FIND since 2013, previously holding positions as Chief Medical Officer and head of the organization's tuberculosis (TB) programme. She has been responsible for the clinical evaluation of new tools for the diagnosis of TB, malaria and neglected diseases, as well as activities to enhance access to critical diagnostics, including laboratory strengthening, in-country validation, and implementation. Catharina has also managed R&D projects for several new point-of-care technologies and molecular diagnostic approaches.

She is a member of the WHO Strategic Advisory Group of Experts on *In Vitro* Diagnostics (SAGE IVD), as well as sitting on several other WHO/UN boards. She is also a *Lancet* Commissioner for TB and Precision Global Health, and Co-chair of the New

Diagnosics Working Group of the Stop TB Partnership.

Prior to joining FIND, Catharina worked as programme coordinator for the Department of Infectious and Tropical Diseases in Munich, Germany, and established a TB research unit at Mbeya Medical Research Program in Tanzania.

She holds a Doctor of Medicine degree in internal medicine (Ludwig Maximilians University Munich, Germany) and diplomas in public health (Charite, Berlin, Germany) and in management & leadership (University of Heidelberg).

Marijke Wijnroks, *Chief of Staff, Global Fund*



Marijke Wijnroks became Chief of Staff at the Global Fund in 2013. From June 2017 through February 2018, she served as Interim Executive Director. Her distinguished career includes more than 30 years of experience in global health and development, serving in government, at the United Nations and in civil society, and working in Africa, Asia, Latin America and Europe. Since joining the Global Fund, Dr. Wijnroks has had a particular focus on gender and human rights, and on engaging diverse partners in the cause of global health. She effectively acts as the organization's second-in-command, overseeing day-to-day work and chairing decision-making groups such as the Management Executive Committee and the Grant Approvals Committee when needed.

Before joining the Global Fund, Dr. Wijnroks was Ambassador for HIV/AIDS, and Deputy Director of the Social Development Department in the Ministry of Foreign Affairs in the Netherlands. In that position she oversaw policy and strategy development in areas related to HIV and AIDS, sexual and reproductive health and rights, gender, education and civil society. She served on the Global Fund Board for several terms, and for two years as Vice - Chair of the Board's Ethics Committee. She earned a medical degree from Maastricht University in the Netherlands and a degree in tropical health and medicine from the Institute for Tropical Medicine in Antwerp, Belgium. Dr. Wijnroks started her career with Médecins Sans Frontières as a field doctor in Sudan. She also spent five years in El Salvador as a technical adviser for PAHO/WHO developing health systems, and two years as a project manager in Bangladesh focusing on maternal and child health.

SCALING UP SYNERGIES BETWEEN THE GLOBAL FUND AND INNOVATORS TO BREAK DOWN BARRIERS TO HEALTH INNOVATION FOR THE MOST VULNERABLE

A preprogramme event ahead of the
6th Global Fund Replenishment Conference
Lyon – France | Oct. 8th, 2019



DNDi
Design for Neglected Diseases initiative

FIND
Increase diagnosis, reduce deaths

INTERNATIONAL PARTNERSHIP FOR MICROBICIDES

IVCC


MMV
Medicines for Malaria Venture

PATH
10:10:10

TB Alliance

Images: 1/ Toby Hadden - 2/ Anna Wang - 3/ Pearl Gan - 4/ Sergei Supinsky/AFP/Getty Images

Testimony from affected groups/communities: **Aurélien Beaucamp, President, AIDES**



Aurélien Beaucamp has been the president of AIDES since June 2015. He is the fifth president of the most important European Organization fighting AIDS and viral hepatitis and embodies the new activist generation in the fight against the epidemic. Coincidence or a sign of fate, Aurélien Beaucamp was born on May 1983 20th, the day of publication in Science Review of the Institut Pasteur team's article that showcased the AIDS retrovirus' discovery. 36 years old today, he is the youngest president ever known in the association. He has been an activist in AIDES Paris since 2011, and he has dedicated himself to AIDS prevention and awareness activities. He has also taken responsibilities in strategy and advocacy in the association.

He is associate director in recruitment and human resource advisor on the public and nonprofit organizations field for Michael Page Group.

He has a degree in political sciences and a master's in public and political communication.

Panel Discussions: Innovation upstream and downstream the Global Fund's work – how to achieve optimal synergies

Moderator: **Mark Chataway, Managing Director, Hyderus**



Mark has worked on communications management and consulting projects with a range of clients over three decades including the Rockefeller Foundation, Eli Lilly, World Vision, Merck & Co., three heads of state, five governments, and the World Bank.

Mark's long-standing specialist interest in the prevention of communicable diseases and in better reproductive health has led to projects with numerous companies and organisations such as the Bill & Melinda Gates Foundation, Johns Hopkins University School of Public Health, and the William & Flora Hewlett Foundation. An excellent presenter and trainer, Mark regularly delivers high-level presentations for clients at academic and policy-level meetings and trains company boards of directors.

Mark is an expert in the field of health and development-related marketing and communications work and is one of the founders of Baird's CMC. Besides being an integral part of the firm, Mark is also the director of his own international communications and policy consultancy, Hyderus, which is based out of Wales.

SCALING UP SYNERGIES BETWEEN THE GLOBAL FUND AND INNOVATORS TO BREAK DOWN BARRIERS TO HEALTH INNOVATION FOR THE MOST VULNERABLE

A preprogramme event ahead of the
6th Global Fund Replenishment Conference
Lyon - France | Oct. 8th, 2019



Images: 1/Toby Hadden - 2/ Anna Wang - 3/Pearl Gan - 4/Sergei Supinsky/AFP/Getty Images

Discussion 1: Innovation upstream: from R&D to more powerful tools

Willo Brock, Senior Vice President of External Affairs, TB Alliance



Willo Brock joined TB Alliance in 2014. As the Senior Vice President of External Affairs he is responsible for providing strategic leadership to the TB Alliance's fundraising, advocacy and policy, and community and stakeholder engagement work.

Prior to joining TB Alliance, Mr. Brock worked for large international development organizations like WWF and Habitat for Humanity. His passion is bringing together people, for profit organisations, governments and civil society to tackle global issues of insecurity and inequality and develop effective programs for growth and development.

Mr. Brock started his career working for the Netherlands Ministry of Development in Pakistan and continued working for MDF Training & Consultancy gaining over ten years of management consultancy, training, coaching and project management experience focused on non-profit clients. He worked in over 90 countries globally.

Mr. Brock received his master's in business administration from the Erasmus University in Rotterdam.

François Dabis, Head of Research on HIV and HCV, ANRS



François Dabis is a medical doctor, professor of epidemiology at the School of Public Health (ISPED) of the University of Bordeaux, France. He has been leading from 2001 to 2016 the Inserm-affiliated "HIV, cancer and global health" research team within ISPED. He is Director of the French National AIDS and Viral Hepatitis Research Agency (ANRS) since March 2017 and Chair of the South West (Nouvelle Aquitaine) Regional Coordination to fight HIV/AIDS and STIs (COREVIH) since June 2017.

Dr. Dabis has more than 30 years of experience in research on HIV epidemiology and global health. He has published 750 papers and two leading textbooks in field epidemiology. He is the PI of the NIH-funded IeDEA West Africa Collaboration and member of the Scientific Program Committee of the Conference on Retroviruses and Opportunistic Infections (CROI).

SCALING UP SYNERGIES BETWEEN THE GLOBAL FUND AND INNOVATORS TO BREAK DOWN BARRIERS TO HEALTH INNOVATION FOR THE MOST VULNERABLE

A preprogramme event ahead of the
6th Global Fund Replenishment Conference
Lyon - France | Oct. 8th, 2019



DNDi
Design for Neglected Diseases initiative

FIND
Increase diagnosis reactions

INTERNATIONAL PARTNERSHIP FOR MICROBICIDES

IVCC

MMV
Medicines for Malaria Venture

PATH
10:10+1100

TB Alliance

Images: 1/ Toby Hadden - 2/ Anna Wang - 3/ Pearl Gan - 4/ Sergei Supinsky/AFP/Getty Images

Renuka Gadde, Vice President, Global Health, BD (Becton, Dickinson and Company)




Renuka Gadde joined BD 14 years ago. In her current role, she works with international agencies, thought leaders and governments to strengthen medical practices around the world. Her role focuses on creating access to the neglected populations in the developing and emerging markets. She also wants to establish appropriate policies and standards for safe blood collection and to drive public-private partnerships that improve conditions across health initiatives such as HIV, cancer and TB.

Prior to her current role, Renuka was leading the Emerging Markets Injection Safety platform at BD. During this period, she was instrumental for developing unique product solutions specifically suited for the emerging markets and was the key contact for UNICEF supplies in Copenhagen and for driving programs and policies with UNICEF, New York.

Key programs she has led include developing 4 partnerships with PEPFAR, with the International Council of Nurses and UNICEF. She serves on the board of World Neighbors, an NGO and is also on the Expert Advisory Council of University of Michigan. Renuka began her career in India where she worked for 5 years prior to moving to Singapore to work for BD in 1997. She was the Regional Director for Asia Pacific Immunization at BD.

She has a bachelor's degree in sciences and holds a master's degree in business administration.

Tom McLean, Head, Access and New Paradigms in Vector Control, IVCC



Tom is responsible for ensuring that the new tools emerging from the IVCC portfolio, and other essential vector control tools, are available, affordable, acceptable and adopted by the populations of the disease endemic countries. He develops and manages partnerships with manufacturers of vector control tools, national programmes, funders and donors and implementation partners, as well as academia, to support this process.

He also has 30 years' experience in the chemical industry having worked for several of the industry leaders including ICI, Merck, Rexam and Avecia. Tom has led a number of multinational consortia spanning industrial and academic partners to bring about the development and exploitation of novel chemical technologies targeted at consumer and industrial markets. He focussed initially on chemical and process technology research for speciality chemicals but became progressively more interested in the marketing of technological advances and the introduction of ground-breaking consumer products.

Tom graduated from Oxford University with an MPhil in chemistry and a DPhil in organometallic reaction mechanisms.

SCALING UP SYNERGIES BETWEEN THE GLOBAL FUND AND INNOVATORS TO BREAK DOWN BARRIERS TO HEALTH INNOVATION FOR THE MOST VULNERABLE

A preprogramme event ahead of the
6th Global Fund Replenishment Conference
Lyon – France | Oct. 8th, 2019



DNDi
Design for Neglected Diseases initiative

FIND
Increase diagnosis, reduce deaths

INTERNATIONAL PARTNERSHIP FOR MICROBICIDES

IVCC
International Vaccine Centre

MMV
Medicines for Malaria Venture

PATH
Program on Appropriate Technology Health

TB Alliance

Images: 1/Toby Hadden - 2/ Anna Wang - 3/Pearl Gan - 4/Sergei Supinsky/AFP/Getty Images

Discussion 2: Innovation downstream: from new health tools to impact

Sherwin Charles, *CEO, Nandos and Co-Founder, Goodbye Malaria*



Sherwin is a Board of Trustees member at IVCC. He is also the CEO and Co-Founder of Goodbye Malaria.

Sherwin is a Chartered Accountant from the University of Witwatersrand. He spent 13 years in the banking and financial services industry where he was appointed director of one of the first black empowerment investment banks in their stock brokering company, Real Africa Durolink Security. He also launched Standard Private Bank and was appointed CEO of First Alliance – one of seven companies licensed as pension fund administrators in 2006. Sherwin then returned to South Africa and helped to start Nando's and Restfin PTY Limited.

H.E. Chitalu Chilufya, *Minister of Health, Zambia*



Dr. Chitalu Chilufya was appointed Zambian Minister of Health by the President of the Republic of Zambia His Excellency Mr. Edgar Chagwa Lungu in September 2016. Since 2013, he has been serving as the Member of Parliament for Mansa Central Constituency in the Northern part of Zambia.

He is successfully leading a transformational agenda focused on the tenets of creating a resilient health system anchored on primary health care approach to achieve universal health coverage. Previously he served as the Deputy Minister of Health between 2014 and 2016. Immediately after taking office he outlined nine legacy goals for the Ministry of Health from 2017 to 2021: elimination of malaria; HIV epidemic control; reduce maternal and child illness and death; recruit 30,000 health care workers; Implement the national health insurance scheme and increase insurance coverage; construction of new specialised hospitals and new health facilities; train 500 specialists; halt and reduce the incidence of non-communicable diseases and address alcohol and substance abuse.

In under two years, over 10,000 health workers have been recruited, the National Health Insurance Bill has been enacted by parliament, a local training program for specialists has been started with over 200 in training, the National Alcohol Policy has been approved, there is construction of 300 health posts around the country, and the construction of the National Health Training Institute with a 3000 student capacity as well as upgrading of some level 1 hospitals into level 2 hospitals and construction of regional hubs for improved supply chain management of essential medicines.

Dr. Chitalu is a graduate of the University of Zambia, School of Medicine.

SCALING UP SYNERGIES BETWEEN THE GLOBAL FUND AND INNOVATORS TO BREAK DOWN BARRIERS TO HEALTH INNOVATION FOR THE MOST VULNERABLE

A preprogramme event ahead of the
6th Global Fund Replenishment Conference
Lyon – France | Oct. 8th, 2019



DNDi
Drugs for Neglected Diseases initiative

FIND
Increase diagnosis, reduce deaths

INTERNATIONAL PARTNERSHIP FOR MICROBICIDES

IVCC
International Vaccine Centre

MMV
Medicines for Malaria Venture

PATH
Program for Appropriate Technology

TB Alliance

Images: 1/Toby Hadden - 2/Anna Wang - 3/Pearl Gan - 4/Sergei Supinsky/AFP/Getty Images

Sanne Fournier-Wendes, *Chief of Staff, Unitaid*



Sanne Fournier-Wendes is Chief of Staff at Unitaid and part of the senior management team. She led the development of Unitaid's strategy 2017-2021 and its new operating model, which strengthens Unitaid's alignment with other strategic partners in the global response to HIV/AIDS, Tuberculosis and Malaria, and increases speed and quality of grant making processes. Sanne is also in charge of risk management and oversight.

Prior to joining Unitaid, she spent 7 years in the private sector with Vestergaard, where she led the company's engagement with Global Partnerships. She was a member of the Private Sector Delegation to the Global Fund Board and represented the Private Sector on the Roll Back Malaria Board as Board Alternate. Prior to this, she worked at the Global Fund as Special Assistant to the Director of Operations and as Programme Officer, and as an international consultant, spending two years with UNDP in Burkina Faso.

Sanne holds a Master of Science in economics from the University of Copenhagen, Denmark.

Bernard Pécoul, *Executive Director, DNDi*



Dr. Bernard Pécoul has led the Drugs for Neglected Diseases initiative (DNDi) since its foundation in 2003. Under his guidance, DNDi – a not-for-profit research and development organization – with hundreds of public and private partners, has delivered seven new treatments for the most neglected diseases and for malaria. It has developed a robust portfolio of projects spanning from discovery to implementation for these diseases as well as filaria, paediatric HIV, mycetoma, and Hepatitis C. As part of DNDi's dynamic portfolio approach, Dr. Pécoul is also leading the incubation of a product development partnership to address R&D for new antibiotic treatments.

Prior to DNDi, Dr. Pécoul was Director of the Médecins Sans Frontières (MSF) Campaign for Access to Essential Medicines from 1998 to 2003, a position he took on after that of

Executive Director of MSF-France. While working with MSF, Dr. Pécoul carried out field missions in Africa, Latin America, and Asia. In 1988, he co-founded Epicentre, an MSF-affiliated NGO specialized in epidemiology.

Bernard Pécoul is member of the Joint Coordination Board of the Special Programme for Tropical Disease Research (WHO/TDR) and a former board member of UNITAID's Medicines Patent Pool.

After obtaining his medical degree at the University of Clermont-Ferrand, France, Dr. Pécoul earned a master's degree in public health at Tulane University, USA. In 2012, he was awarded an honorary Doctor of Law degree by the University of Dundee, UK.

SCALING UP SYNERGIES BETWEEN THE GLOBAL FUND AND INNOVATORS TO BREAK DOWN BARRIERS TO HEALTH INNOVATION FOR THE MOST VULNERABLE

A preprogramme event ahead of the
6th Global Fund Replenishment Conference
Lyon - France | Oct. 8th, 2019



DNDi
Design for Neglected Diseases initiative

FIND
Increase diagnosis, reduce deaths

INTERNATIONAL PARTNERSHIP FOR MICROBICIDES

IVCC
International Vaccine Centre

MMV
Medicines for Malaria Venture

PATH
Program on Appropriate Technology Health

TB Alliance

Images: 1/ Toby Hadden - 2/ Anna Wang - 3/ Pearl Gan - 4/ Sergei Supinsky/AFP/Getty Images

Conclusions and closing remarks

David Reddy, CEO of Medicines for Malaria Venture



David joined Medicines for Malaria Venture (MMV) in 2010. Medicines for Malaria Venture is a not-for-profit research foundation that has brought forward 7 new antimalarial drugs to malaria-endemic countries, saving an estimated 1.5 million lives to date. In addition, MMV has broadened the global malaria medicine portfolio and manages, with its partners, 65 projects, and has 10 compounds in clinical development including molecules with novel mechanisms of action, conferring benefits against drug resistant malaria parasites.

David is a New Zealand / Swiss dual national, with 26 years of experience in the development and commercialization of medicines for the treatment of infectious diseases. His resume includes successful leadership of drug development teams, licensing and alliance management, market analytics and business planning, product and disease area management, and interfacing with Governments, NGOs and patient advocacy groups around access to medicines for priority diseases including HIV/AIDS and pandemic influenza.

David is a board member of the Coalition for Epidemic Preparedness Innovations (CEPI) and of the RBM Partnership. David has a PhD in cellular and molecular biology from the University of Auckland, New Zealand.